Ester Caffarel-Salvador received her Ph.D. in Pharmacy from Queen’s University Belfast in 2014. Her research focused on the development of hydrogel-forming microneedles for transdermal therapeutic drug monitoring as an alternative to blood extraction. After completing her Ph.D., Ester collaborated with world leading pharmaceutical companies (L’ÓREAL, Lohmann Therapy Systems) in developing microneedles for transdermal drug delivery. Ester is currently a postdoctoral associate at the laboratory of Prof. Robert Langer at the Koch Institute for Integrative Cancer Research at MIT. She is coordinating a project funded by Novo Nordisk which focuses on the development of drug delivery devices for the administration of peptides.
